Progression of Hematopoietic Diseases in Shanghai, China

This study has been completed.
Sponsor:
Collaborators:
Fudan University
University of Cincinnati
ExxonMobil Biomedical Sciences, Inc.
British Petroleum-Amoco
Chevron
ConocoPhillips
Exxon Mobil
Marathon Ashland
Shell Chemicals
Information provided by (Responsible Party):
University of Colorado, Denver
ClinicalTrials.gov Identifier:
NCT00365014
First received: August 14, 2006
Last updated: July 19, 2013
Last verified: July 2013
  Purpose

The purpose of this study is to identify and characterize blood diseases presenting at Shanghai hospitals and to compare them with respect to clinical presentation, phenotype, molecular characteristics, benzene or other exposures and genetic susceptibility.


Condition
Hematologic Diseases

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Analysis of Disease Progression for Aplastic Anemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia and Benzene Poisoning in Shanghai, China.

Resource links provided by NLM:


Further study details as provided by University of Colorado, Denver:

Primary Outcome Measures:
  • blood diseases presenting at Shanghai hospitals [ Time Frame: hospital stay ] [ Designated as safety issue: No ]
    characterization of people with blood diseases presenting at Shanghai hospitals


Enrollment: 10757
Study Start Date: August 2003
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
Blood disease patients
People with blood diseases presenting at Shanghai hospitals

Detailed Description:

The purpose of this study is to identify and characterize blood diseases presenting at Shanghai hospitals and to compare them with respect to clinical presentation, phenotype, molecular characteristics, benzene or other exposures and genetic susceptibility. The format for these studies is a set of clinical series superimposed on a case-control design that enables integration of detailed clinical and molecular characterizations of disease pathogenesis together with an evaluation of potential confounding and interacting factors within a structured statistical analysis of benzene exposure.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with blood diseases

Criteria

Inclusion Criteria:

Men and women 18 years or older Diagnosis of hematologic abnormality

Exclusion Criteria:

Children Non hematologic diseases

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00365014

Locations
China
Joint Sino-US Clinical and Molecular Laboratory (JCML)
Shanghai, China, 200032
Sponsors and Collaborators
University of Colorado, Denver
Fudan University
University of Cincinnati
ExxonMobil Biomedical Sciences, Inc.
British Petroleum-Amoco
Chevron
ConocoPhillips
Exxon Mobil
Marathon Ashland
Shell Chemicals
Investigators
Principal Investigator: Richard D Irons, PhD University of Colorado at Denver and Health Sciences Ctr.
  More Information

No publications provided

Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT00365014     History of Changes
Other Study ID Numbers: 02-0036
Study First Received: August 14, 2006
Last Updated: July 19, 2013
Health Authority: United States: Institutional Review Board
China: Ministry of Health

Keywords provided by University of Colorado, Denver:
aplastic anemia
myelodysplastic syndromes
cytopenias
acute myeloid leukemia
myelodysplastic/myeloproliferative diseases
benzene poisoning

Additional relevant MeSH terms:
Hematologic Diseases
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Preleukemia
Bone Marrow Diseases
Leukemia
Leukemia, Myeloid
Neoplasms
Neoplasms by Histologic Type
Precancerous Conditions

ClinicalTrials.gov processed this record on October 23, 2014